SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (16620)2/16/2004 12:42:08 PM
From: Bluegreen  Read Replies (2) | Respond to of 17367
 
George, Neuprex had SUBPART E designation which only requires clinical benefit. Experts that saw the results were agast at the delay in getting Neuprex to the SEVERELY already high Glasgow scored patients. Why didn't the routine administered antibiotics and OTHER meds have the SAME handicap???? Seems awful strange that the FDA doesn't address the subpart E issue.



To: aknahow who wrote (16620)2/16/2004 1:11:28 PM
From: Bluegreen  Respond to of 17367
 
Let's not forget this also.>>>>>>>>http://www.fda.gov/cber/summaries/120600bio03.htm


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News